期刊文献+

手术去势治疗药物去势抵抗性前列腺癌的临床研究 被引量:11

在线阅读 下载PDF
导出
摘要 药物去势是晚期转移性前列腺癌的一线治疗方案,但是经过中位18~24个月后,几乎所有患者病变都将复发及进展演变为药物去势抵抗性前列腺癌(medical castration resistant prostate cancer,CRPC),
出处 《中华男科学杂志》 CAS CSCD 2014年第5期467-469,共3页 National Journal of Andrology
作者简介 王秀新(1974-),男,湖北十堰市人,副主任医师,本科,从事泌尿系肿瘤临床研究。Email:urologist02@aliyun.com 通讯作者:李云飞,Email:lyf694110@aliyun.com
  • 相关文献

参考文献3

二级参考文献106

  • 1杨念钦,王益鑫.激素非依赖性前列腺癌分子机制的研究现状[J].中华男科学杂志,2006,12(6):551-554. 被引量:4
  • 2宋海珠,陈龙邦.激素抵抗型前列腺癌的研究进展[J].中华男科学杂志,2007,13(1):57-60. 被引量:17
  • 3曾正陪 方圻.肾上腺皮质疾病.现代内科学[M].北京:人民军医出版社,1996.2584-2623.
  • 4Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29: 2040-5.
  • 5Bolla M, van Poppel H, Tombal B. 10-year results of adjuvant radiotherapy after radical prostatectomy in pT3NO prostate cancer (EORTC 22991) (abstract). Int J Radiat Biol Phys 2010; 78: s29.
  • 6Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G etal. Adjuvant radiotherapy for pathological T3NOMO prostate cancer significantly reduces risk of metastases and improves survivah Iong-term followup of a randomized clinical trial. J Urol 2009; 181: 956-62.
  • 7Whittington R, Broderick GA, Arger P, Malkowicz SB, Epperson RD et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44:1107-10.
  • 8Zelefsky M J, Leibel SA, Burman CM, Kutcher G J, Harrison A et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29: 755-61.
  • 9D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A etal. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with crinicarly localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-7.
  • 10Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP etal. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-18.

共引文献22

同被引文献95

  • 1杜广军,李连军.间歇性与持续性雄激素剥夺治疗在前列腺癌治疗中的比较[J].泌尿外科杂志(电子版),2014(1):57-57. 被引量:1
  • 2华立新,吴宏飞,眭元庚,徐正铨,张炜,钱立新,殷长军,居小兵,张杰秀.药物去势和手术去势对前列腺癌患者性激素的影响[J].中华泌尿外科杂志,2005,26(12):812-815. 被引量:12
  • 3余凯远,翁志梁,王思齐,余志贤,陈伟,吴秀玲,李澄棣.间歇性与持续性雄激素阻断治疗晚期前列腺癌疗效比较[J].中华泌尿外科杂志,2006,27(11):761-764. 被引量:31
  • 4贺骏,阮秋蓉,杨秀萍,聂秀.Pin1和Cyclin D1在人类5种常见肿瘤中的表达及其意义[J].中国组织化学与细胞化学杂志,2006,15(6):608-612. 被引量:10
  • 5Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63 ( 1 ) : 11-30.
  • 6DeVita VT Jr, Canellos GP. Hematology in 2010: New therapies and standard of care in oncology. Nat Rev Clin Oncol, 2011, 8 (2) : 67-68.
  • 7Steriti R. Nutritional support for chronic myelogenous and other leukemias: A review of the scientific literature. Altem Med Re,2002, 7 (5) : 404-409.
  • 8Carassou P, Meijer L, Le Moulec S, et al. Cell cycle and mole- cular targets : CDK inhibition. Bull Cancer, 2012, 99 (2) : 163- 171.
  • 9Eisenbrand G, Hippe F, Jakobs S, et al. Molecular mechanisms of indirubin and its derivatives: Novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol, 2004, 130( 11 ) : 627-635.
  • 10You YC, Mi JX, Wan JH, et al. Indirubin in the treatment of chronic myelocytic leukemia (CML) - estimation of labelling index of bone marrow cells by 3 H-TdR. Zhonghua Zhong Liu Za Zhi, 1987, 9(6) : 418-420.

引证文献11

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部